Also
Biogen Idec Inc., which withdrew multiple sclerosis drug Tysabri in February, said it would cut about 650 jobs, or 17% of its workforce, and divest its drug Amevive for the skin condition psoriasis.
Biogen Idec Inc., which withdrew multiple sclerosis drug Tysabri in February, said it would cut about 650 jobs, or 17% of its workforce, and divest its drug Amevive for the skin condition psoriasis.
